RecruitingPhase 1NCT03258658

Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures

A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral


Sponsor

Wake Forest University Health Sciences

Enrollment

10 participants

Start Date

Aug 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This is a Phase I clinical study to determine the safety and efficacy of using autologous, engineered urethral constructs for the treatment of urethral strictures in adult males. The proposed study design is a prospective non-randomized and uncontrolled single-center investigation. Autologous urothelial cells (UCs) and smooth muscle cells (SMCs), obtained from enrolled male subjects' bladder tissue samples, will be culture expanded in vitro and used to seed tubular PGA scaffolds to create autologous urethral constructs for the repair of urethral strictures.


Eligibility

Sex: MALEMin Age: 21 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Autologous Engineered Urethral Construct for people with male urogenital diseases, urethral injury, and other related conditions. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAutologous Engineered Urethral Construct

urethral construct


Locations(2)

University of California San Francisco

San Francisco, California, United States

Wake Forest Institute for Regenerative Medicine (WFIRM)

Winston-Salem, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03258658


Related Trials